Fig. 4: CgHxt4/6/7 promotes azole susceptibility in C. glabrata 040 clinical isolate by mediating azoles uptake.

a Comparison of the susceptibility to antifungal azole drugs, at the indicated concentrations, of the C. glabrata 040 clinical isolate, the derived mutant strain 040_Δcghxt4/6/7 and the evolved resistant strain 040_Psc on YPD agar plates by spot assays. The inoculum was prepared as described in the Methods section. Cell suspensions used to prepare the spots correspond to 1:5 (b) and 1:25 (c) dilutions of the cell suspensions used in (a). The displayed images are representative of at least three independent experiments. b Time-course accumulation ratio of [³H]-Fluconazole in non-adapted (black circles) 040 or derived (grey squares) 040_Δcghxt4/6/7 mutant cells during cultivation in liquid YPD medium in the presence of unlabelled fluconazole. The accumulation ratio values are averages of, at least, n = 3 independent experiments. Error bars represent the corresponding standard deviations. Significance levels are attributed as follows: *p value < 0.05; **p value < 0.01. c Comparison of the susceptibility to antifungal azole drugs, at the indicated concentrations, of the C. glabrata KUE100::URA-_Δcghxt4/6/7 mutant strain harbouring the pGREG576_PDC1_CgHXT4/6/7 or pGREG576_PDC1_mut_CgHXT6/7 on BM agar plates (without uracil, for plasmid maintenance) by spot assays. The inocula were prepared as described in the Methods section. Cell suspensions used to prepare the spots were 1:5 (b) and 1:25 (c) dilutions of the cell suspensions used in (a). The displayed images are representative of at least three independent experiments.